Trinity Biotech profile

CLINICAL healthcare company Trinity Biotech reports first quarter results on Wednesday. The Bray-based company saw pre-tax profits rise to $8 million (€6.25m) last year, up from $5.7min 2002.

Revenues went up 26% to $65.7 million, driven by a combination of organic growth and acquisitions during the year. The company continued its acquisition programme in 2004 and signed two deals earlier this month, spending a total of $20m. Its acquisition of Fitzgerald Industries will allow it to source raw material more efficiently and cut input costs, while the decision to buy Adaltis, an American distribution company, will beef up Trinity’s presence in the infectious disease sector.

Trinity Biotech is a developer of tests for infectious and sexually transmitted diseases. It makes over 500 diagnostic products used in patient care and clinical laboratory tests and generates sales in 80 countries. It has manufacturing facilities in Bray as well as the American states of New York and California. The company is quoted on New York’s Nasdaq and the Irish Stock Exchange.